Photosensitizers for photodynamic immune modulation

John R. North; Ronald Boch; David W. C. Hunt; Leslie G. Ratkay; Guillermo O. Simkin; Jing-Song Tao; Anna M. Richter; Julia G. Levy

doi:10.1117/12.388020

13 June 2000 Photosensitizers for photodynamic immune modulation

John R. North, Ronald Boch, David W. C. Hunt, Leslie G. Ratkay, Guillermo O. Simkin, Jing-Song Tao, Anna M. Richter, Julia G. Levy

Author Affiliations +

Proceedings Volume 3914, Laser-Tissue Interaction XI: Photochemical, Photothermal, and Photomechanical; (2000) https://doi.org/10.1117/12.388020
Event: BiOS 2000 The International Symposium on Biomedical Optics, 2000, San Jose, CA, United States

Abstract

PDT may be an effective treatment for certain immune-mediated disorders. The immunomodulatory action of PDT is likely a consequence of effects exerted at a number of levels including stimulation of specific cell signaling pathways, selective depletion of activated immune cells, alteration of receptor expression by immune and non-immune cells, and the modulation of cytokine availability. QLT0074, a potent photosensitizer that exhibits rapid clearance kinetics in vivo, is in development for the treatment of immune disorders. In comparison to the well-characterized and structurally related photosensitizer verteporfin, lower concentrations of QLT0074 were required to induce apoptosis in human blood T cells and keratinocytes using blue light for photoactivation. Both photosensitizers triggered the stress activated protein kinase (SAPK) and p38 (HOG1) pathways but not extracellularly regulated kinase (ERK) activity in mouse Pam212 keratinocytes. In cell signaling responses, QLT0074 was active at lower concentrations than verteporfin. For all in vitro test systems, the stronger photodynamic activity of QLT0074 was associated with a greater cell uptake of this photosensitize than verteporfin. In mouse immune models, sub-erythemogenic doses of QLT0074 in combination with whole body blue light irradiation inhibited the contact hypersensitivity response and limited the development of adjuvant-induced arthritis. QLT0074 exhibits activities that indicate it may be a favorable agent for the photodynamic treatment of human immune disease.

Citation Download Citation

John R. North, Ronald Boch, David W. C. Hunt, Leslie G. Ratkay, Guillermo O. Simkin, Jing-Song Tao, Anna M. Richter, and Julia G. Levy "Photosensitizers for photodynamic immune modulation", Proc. SPIE 3914, Laser-Tissue Interaction XI: Photochemical, Photothermal, and Photomechanical, (13 June 2000); https://doi.org/10.1117/12.388020

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available